A multiplex assay for the diagnosis of mucopolysaccharidoses and mucolipidoses

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Langereis, Eveline J ^a   Wagemans, Tom ^a   Kulik, Wim ^a   Lefeber, Dirk J ^b   Van Lenthe, Henk ^a   Oussoren, Esmee ^c   Van Der Ploeg, Ans T ^c   Ruijter, George J ^c   Wevers, Ron A ^b   Wijburg, Frits A ^a   Van Vlies, Naomi ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DERMATAN SULFATE; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; KERATAN SULFATE;

ADOLESCENT; ADULT; AGED; ARTICLE; BINDING ASSAY; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIMETHYLMETHYLENE BLUE DYE BINDING ASSAY; ENZYME ASSAY; FALSE POSITIVE RESULT; HUMAN; HUNTER SYNDROME; HURLER SYNDROME; INBORN ERROR OF METABOLISM; INFANT; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MAROTEAUX LAMY SYNDROME; MORQUIO SYNDROME; MUCOLIPIDOSIS; MUCOLIPIDOSIS TYPE 2; MUCOLIPIDOSIS TYPE 3; MUCOPOLYSACCHARIDOSIS; MUCOPOLYSACCHARIDOSIS TYPE 7; SANFILIPPO SYNDROME; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; URINALYSIS; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOLATION AND PURIFICATION; MIDDLE AGED; MUCOLIPIDOSES; MUCOPOLYSACCHARIDOSES; NEWBORN; PRESCHOOL CHILD; PROCEDURES; URINE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DERMATAN SULFATE; DIAGNOSIS, DIFFERENTIAL; HEPARITIN SULFATE; HUMANS; INFANT; INFANT, NEWBORN; KERATAN SULFATE; MIDDLE AGED; MUCOLIPIDOSES; MUCOPOLYSACCHARIDOSES; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 84947809464     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0138622     Document Type: Article

References (27)

1. Neufeld EF, Muenzer J. The Mucopolysaccharidoses. In: Valle D, Beaudet A, Vogelstein B, Kinzler K, Antonarakis S, Ballabio A, et al., editors. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill; 2014. doi: 10.1036/ommbid.165
2. Braulke T, Raas-Rothschild A, Kornfeld S. I-cell disease and pseudo-Hurler polydystrophy: Disorders of lysosomal enzyme phosphorilation and localization. In: Valle D, Beaudet A, Vogelstein B, Kinzler K, Antonarakis S, Ballabio A, et al., editors. The Metabolic & Molecular Basis of Inherited Disease. 2014. pp. 3469-82.
3. De Jong JGN, Wevers RA, Liebrand-van Sambeek R. Measuring urinary glycosaminoglycans in the presence of protein: An improved screening procedure for mucopolysaccharidoses based on dimethylmethylene blue. Clin Chem. 1992; 38: 803-807. PMID: 1597005
4. De Jong JG, Wevers RA, Laarakkers C, Poorthuis BJ. Dimethylmethylene blue-based spectrophotometry of glycosaminoglycans in untreated urine: a rapid screening procedure for mucopolysaccharidoses. Clin Chem. 1989; 35: 1472-7. Available: http://www.ncbi.nlm.nih.gov/pubmed/2503262 PMID: 2503262
5. Tomatsu S, Okamura K, Taketani T, Orii KO, Nishioka T, Gutierrez MA, et al. Development and Testing of New Screening Method for Keratan Sulfate in Mucopolysaccharidosis IVA. Pediatr Res. 2004; 55: 592-597. doi: 10.1203/01.PDR.0000113767.60140.E9 PMID: 14711889
6. Oguma T, Tomatsu S, Montano AM, Okazaki O. Analytical method for the determination of disaccharides derived from keratan, heparan, and dermatan sulfates in human serum and plasma by high-performance liquid chromatography/turbo ionspray ionization tandem mass spectrometry. Anal Biochem. 2007; 368: 79-86. doi: 10.1016/j.ab.2007.05.016 PMID: 17603992
7. Auray-Blais C, Bhérer P, Gagnon R, Young SP, Zhang HH, An Y, et al. Efficient analysis of urinary glycosaminoglycans by LC-MS/MS in mucopolysaccharidoses type I, II and VI. Mol Genet Metab. Elsevier Inc.; 2011; 102: 49-56. doi: 10.1016/j.ymgme.2010.09.003 PMID: 20934363
8. Zhang H, Wood T, Young SP, Millington DS. A straightforward, quantitative ultra-performance liquid chromatography-tandem mass spectrometric method for heparan sulfate, dermatan sulfate and chondroitin sulfate in urine: An improved clinical screening test for the mucopolysaccharidoses. Mol Genet Metab. Elsevier B.V.; 2015; 114: 123-8. doi: 10.1016/j.ymgme.2014.09.009 PMID: 25458519
9. Chuang C-K, Lin H-Y, Wang T-J, Tsai C-C, Liu H-L, Lin S-P. A modified liquid chromatography/tandem mass spectrometry method for predominant disaccharide units of urinary glycosaminoglycans in patients with mucopolysaccharidoses. Orphanet J Rare Dis. 2014; 9: 135. doi: 10.1186/s13023-014-0135-3 PMID: 25178307
10. Hintze JP, Tomatsu S, Fujii T, Montaño AM, Yamaguchi S, Suzuki Y, et al. Comparison of liquid chromatography-tandem mass spectrometry and sandwich ELISA for determination of keratan sulfate in plasma and urine. Biomark Insights. 2011; 6: 69-78. doi: 10.4137/BMI.S7451 PMID: 21792275
11. Martell LA, Cunico RL, Ohh J, Fulkerson W, Furneaux R, Foehr ED. Validation of an LC-MS/MS assay for detecting relevant disaccharides from keratan sulfate as a biomarker for Morquio A syndrome. Bioanalysis. 2011; 3: 1855-66. doi: 10.4155/bio.11.172 PMID: 21877895
12. Van der Horst GT, Kleijer WJ, Hoogeveen AT, Huijmans JG, Blom W, van Diggelen OP. Morquio B syndrome: a primary defect in beta-galactosidase. Am J Med Genet. 1983; 16: 261-75. doi: 10.1002/ajmg. 1320160215 PMID: 6418007
13. De Ru MH, van der Tol L, van Vlies N, Bigger BW, Hollak CEM, Ijlst L, et al. Plasma and urinary levels of dermatan sulfate and heparan sulfate derived disaccharides after long-term enzyme replacement therapy (ERT) in MPS I: correlation with the timing of ERT and with total urinary excretion of glycosaminoglycans. J Inherit Metab Dis. 2013; 36: 247-55. doi: 10.1007/s10545-012-9538-2 PMID: 22991166
14. Lawrence R, Lu H, Rosenberg RD, Esko JD, Zhang L. Disaccharide structure code for the easy representation of constituent oligosaccharides from glycosaminoglycans. Nat Methods. Nature Publishing Group; 2008; 5: 291-2. doi: 10.1038/nmeth0408-291
15. Bodamer OA, Giugliani R, Wood T. The laboratory diagnosis of mucopolysaccharidosis III (Sanfilippo syndrome): A changing landscape. Mol Genet Metab. Elsevier Inc.; 2014; 113: 34-41. doi: 10.1016/j. ymgme.2014.07.013 PMID: 25127543
16. De Jong JGN, Hasselman JJF, Van Landeghem AAJ, Vader HL, Wevers RA. The spot test is not a reliable screening procedure for mucopolysaccharidoses. Clin Chem. 1991; 37: 572-575. PMID: 1901775
17. Valstar MJ, Bruggenwirth HT, Olmer R, Wevers RA, Verheijen FW, Poorthuis BJ, et al. Mucopolysaccharidosis type IIIB may predominantly present with an attenuated clinical phenotype. J Inherit Metab Dis. 2010; 33: 759-67. doi: 10.1007/s10545-010-9199-y PMID: 20852935
18. Esko J, Kimata K, Lindahl U. Proteoglycans and sulfated glycosaminoglycans. In: Varki A, Cummings R, Esko JD, editors. Essentials of glycobiology. New York: Cold Spring Harbor; 2009.
19. Tomatsu S, Gutierrez MA, Ishimaru T, Peña OM, Montaño AM, Maeda H, et al. Heparan sulfate levels in mucopolysaccharidoses and mucolipidoses. J Inherit Metab Dis. 2005; 28: 743-57. doi: 10.1007/s10545-005-0069-y PMID: 16151906
20. Hieber V, Distler J, Jourdian GW, Schmickel R. Accumulation of 32S-mucopolysaccharides in cultured mucolipidosis cells. Birth Defects Orig Artic Ser. 1975; 11: 307-10. Available: http://www.ncbi.nlm.nih.gov/pubmed/127632 PMID: 127632
21. Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S, et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet. 1999; 105: 151-6. Available: http://www.ncbi.nlm.nih.gov/pubmed/10480370 PMID: 10480370
22. Lamanna WC, Lawrence R, Sarrazin S, Esko JD. Secondary storage of dermatan sulfate in Sanfilippo disease. J Biol Chem. 2011; 286: 6955-62. doi: 10.1074/jbc.M110.192062 PMID: 21193389
23. Tomatsu S, Shimada T, Mason RW, Montaño AM, Kelly J, La Marr Wa, et al. Establishment of glycosaminoglycan assays for mucopolysaccharidoses. Metabolites. 2014; 4: 655-79. doi: 10.3390/metabo4030655 PMID: 25116756
24. Fuller M, Rozaklis T, Ramsay SL, Hopwood JJ, Meikle PJ. Disease-specific markers for the mucopolysaccharidoses. Pediatr Res. 2004; 56: 733-8. doi: 10.1203/01.PDR.0000141987.69757.DD PMID: 15347771
25. Langereis EJ, van Vlies N, Church HJ, Geskus RB, Hollak CEM, Jones S a, et al. Biomarker responses correlate with antibody status in mucopolysaccharidosis type I patients on long-term enzyme replacement therapy. Mol Genet Metab. Elsevier Inc.; 2015; 114: 129-37. doi: 10.1016/j.ymgme.2014.10.012 PMID: 25467058
26. Jura-Półtorak A, Komosinska-Vassev K, Kotulska A, Kucharz EJ, Klimek K, Kopec-Medrek M, et al. Alterations of plasma glycosaminoglycan profile in patients with rheumatoid arthritis in relation to disease activity. Clin Chim acta. 2014; 433: 20-7. doi: 10.1016/j.cca.2014.02.027 PMID: 24607326
27. Nelson A, Berkestedt I, Schmidtchen A, Ljunggren L, Bodelsson M. Increased levels of glycosaminoglycans during septic shock: relation to mortality and the antibacterial actions of plasma. Shock. 2008; 30: 623-7. doi: 10.1097/SHK.0b013e3181777da3 PMID: 18497712